XML 166 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 29, 2023
Feb. 01, 2023
May 21, 2021
Dec. 31, 2018
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2018
Jul. 21, 2023
Significant Agreements [Line Items]                  
Services payments         $ 4,278        
Assets         87,518,032 $ 87,518,032 $ 26,310,447    
Research and development expenses           1,949,406 4,129,688    
Accounts payable         $ 1,800,000 $ 1,800,000      
Accrued expenses             669,000    
Royalty net sales percentage           4.00%      
Percentage of product         2.00% 2.00%      
Royalty rates               25.00%  
Aggregate payments               $ 51,250,000  
Development milestones costs           $ 500,000      
License fee           100,000      
Total amount of fee expenses $ 800,000                
Maturity term Jul. 14, 2025                
Expense related to contract           3,100,000      
Minimum [Member]                  
Significant Agreements [Line Items]                  
Other party payments   $ 2,100,000              
Royalties percentage   2.00%              
Maximum [Member]                  
Significant Agreements [Line Items]                  
Other party payments   $ 4,750,000              
Royalties percentage   4.00%              
Regulatory milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           1,250,000      
Commercial milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           58,000,000      
Vendor Agreement [Member]                  
Significant Agreements [Line Items]                  
Sales-related services fee                 $ 29,100,000
Ology Bioservices, Inc [Member]                  
Significant Agreements [Line Items]                  
Aggregate agreement amount initial agreement           4,000,000      
Services payments           100,000      
Aggregate amount     $ 2,800,000            
Cost plus, percentage     15.00%            
Assets         $ 137,000 137,000 137,000    
Research and development expenses           15,000 1,329,000    
Accounts payable         $ 685,000 $ 685,000 $ 476,000    
CHMC Agreement [Member]                  
Significant Agreements [Line Items]                  
Commercial sale term           10 years      
Royalty net sales percentage           5.00%      
Royalty rates           50.00%      
Revenue rate           25.00%      
Option fee           $ 50,000      
Aggregate payments           $ 59,750,000      
Oxford University Innovation Limited [Member]                  
Significant Agreements [Line Items]                  
Royalty net sales percentage               6.00%  
Royalty rates               3.00%  
Royalty payment               $ 250,000  
Maintenance fee               10,000  
Oxford University Innovation Limited [Member] | Regulatory milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs       $ 9,500,000          
Oxford University Innovation Limited [Member] | Commercial milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs       39,500,000          
Oxford University Innovation Limited [Member] | Development milestone [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs       $ 2,250,000          
Oxford University Innovation Limited [Member] | OUI Agreement [Member]                  
Significant Agreements [Line Items]                  
Maintenance fee               $ 20,000  
St. Jude Children’s Hospital [Member]                  
Significant Agreements [Line Items]                  
Royalty rates           5.00%      
Aggregate payments           $ 1,900,000      
Percentage of consideration received         15.00% 15.00%      
License fee           $ 5,000      
Annual maintenance fee           10,000      
St. Jude Children’s Hospital [Member] | Regulatory milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           600,000      
St. Jude Children’s Hospital [Member] | Commercial milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           1,000,000      
St. Jude Children’s Hospital [Member] | Development milestone [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           $ 300,000      
University of Texas Health Science Center at San Antonio [Member]                  
Significant Agreements [Line Items]                  
Royalty net sales percentage           3.00%      
Royalty rates           20.00%      
Aggregate payments           $ 2,200,000      
University of Texas Health Science Center at San Antonio [Member] | Commercial milestones [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           1,500,000      
University of Texas Health Science Center at San Antonio [Member] | Development milestone [Member]                  
Significant Agreements [Line Items]                  
Development milestones costs           $ 700,000      
University of Texas Health Science Center at San Antonio [Member] | UT Health Agreement [Member]                  
Significant Agreements [Line Items]                  
Royalty net sales percentage           5.00%      
Co Development Agreement [Member]                  
Significant Agreements [Line Items]                  
Research and development expenses           $ 21,000      
Laborator Corporation of America [Member]                  
Significant Agreements [Line Items]                  
Description of licensed products           •        After the first sale of Proclarix as a laboratory developed test, Labcorp will pay an amount in the mid-six figures,•        after Labcorp achieves a certain amount in the low seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures,•        after a certain amount in the mid-seven figures in net sales of Licensed Products, Labcorp will pay Proteomedix an amount in the low seven figures.